Skip to main content
Clinical Trials/NCT00490594
NCT00490594UnknownPhase 1

A Multi-Center Open Study to Evaluate the SeriACL™ Device for Primary Anterior Cruciate Ligament Repair

Serica Technologies, Inc.3 sites in 2 countries30 target enrollmentStarted: June 1, 2007Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Sponsor
Enrollment
30
Locations
3
Primary Endpoint
KT-1000 Arthrometer

Study Overview

Brief Summary

The SeriACL device was developed as an alternative to an autograft (i.e., tissue that is taken from a patient's own body) or an allograft (i.e., tissue that is taken from a cadaver) for ACL reconstruction. The SeriACL device is made of silk yarns, knit and processed with SeriCoat™ surface treatment which makes it easier to wet the material. The SeriACL device is designed to be a temporary support structure to replace the torn ACL and to stabilize the knee joint following surgical repair. It is designed to use the body's own healing process to regenerate the patient's own new ligament tissue. As the new tissue grows and the support structure is needed less over time, the SeriACL device is bioresorbed (i.e., broken down) by the patient's body. The SeriACL device is designed to be installed with standard surgical techniques for ACL repair.

This study is designed to test the safety of the SeriACL device in primary total ACL repair in patients with a torn ACL. The study will evaluate whether repair of the ACL with the SeriACL device will return the knee to normal function and what, if any, side effects will occur.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Complete ACL rupture
  • Injured knee range of motion >= 75% of contralateral knee
  • MCL tear grading <= 2
  • Sign informed consent.

Exclusion Criteria

  • Prior ACL reconstruction
  • Complete PCL tear
  • Locked bucket handle tear or complex tears of the menisci.
  • Contralateral knee ligament injury
  • Known joint disease
  • Known allergy to silk
  • Active drug or alcohol abuse

Outcomes

Primary Outcomes

KT-1000 Arthrometer

Time Frame: 12 months

Safety - measured by device related SAEs

Time Frame: 12 months

Secondary Outcomes

  • Knee Surveys(12 months)
  • Return to Work(12 months)

Investigators

Sponsor
Serica Technologies, Inc.
Sponsor Class
Industry

Study Sites (3)

Loading locations...

Similar Trials